MDxHealthMDXH
MDXH
About: MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Employees: 312
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
2.54% less ownership
Funds ownership: 45.44% [Q4 2024] → 42.9% (-2.54%) [Q1 2025]
13% less funds holding
Funds holding: 24 [Q4 2024] → 21 (-3) [Q1 2025]
44% less capital invested
Capital invested by funds: $53.2M [Q4 2024] → $30.1M (-$23.1M) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for MDXH.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change
IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May.
Neutral
Seeking Alpha
1 month ago
MDxHealth SA (MDXH) Q1 2025 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Corporate Participants John Fraunces - LifeSci Advisors, IR Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Mark Massaro - BTIG Dan Brennan - UBS Jason Bednar - Piper Sandler Thomas Vranken - KBC Securities Nelson Cox - Lake Street Capital Markets Operator Good day and welcome to the MDxHealth First Quarter 2025 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Mr.
Negative
Zacks Investment Research
1 month ago
MDxHealth SA (MDXH) Reports Q1 Loss, Tops Revenue Estimates
MDxHealth SA (MDXH) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.31 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
MDxHealth Reports Q1-2025 Results
Year-over-year Q1 revenues increase by 22% to $24.3 million 71% year-over-year improvement in adjusted EBITDA in first quarter Conference call with Q&A today at 4:30 PM ET / 22:30 CET
Positive
Zacks Investment Research
4 months ago
Down -15.22% in 4 Weeks, Here's Why You Should You Buy the Dip in MDxHealth SA (MDXH)
MDxHealth SA (MDXH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neutral
Seeking Alpha
4 months ago
MDxHealth SA (MDXH) Q4 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants John Fraunces - LifeSci Advisors, IR Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Vidyun Bais - BTIG Dan Brennan - TD Cowen Operator Good day. And welcome to the MDxHealth Fourth Quarter and Full Year 2024 Earnings Call.
Negative
Zacks Investment Research
4 months ago
MDxHealth SA (MDXH) Reports Q4 Loss, Tops Revenue Estimates
MDxHealth SA (MDXH) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.39 per share a year ago.
Neutral
GlobeNewsWire
4 months ago
Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results
Fourth quarter revenue growth of 28% to $24.7 million 2024 revenue growth of 28% to $90.0 million 68% improvement in adjusted EBITDA in fourth quarter Conference call with Q&A today at 4:30 PM EST / 22:30 CET
Neutral
GlobeNewsWire
5 months ago
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, representing year-over-year growth of 28% for both periods.
Positive
Seeking Alpha
6 months ago
MDxHealth: Strong Buy On Its Cutting-Edge Urology Diagnostics
MDxHealth SA offers a comprehensive portfolio of precision diagnostics targeting all stages of prostate cancer and advanced UTI detection, addressing a $4.9 billion TAM. The company's flagship products, ConfirmMDx (post-biopsy detection), SelectMDx (pre-biopsy screening), and GPS (treatment planning), are driving clinical adoption. MDxHealth achieved 21% YoY revenue growth in Q3 2024, with management forecasting positive EBITDA by 2025 through disciplined cash management and market penetration.
Charts implemented using Lightweight Charts™